IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Holdings Lowered by Stifel Financial Corp

Stifel Financial Corp decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 15.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 33,616 shares of the company's stock after selling 5,996 shares during the quarter. Stifel Financial Corp's holdings in IDEXX Laboratories were worth $16,983,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of IDXX. Quantinno Capital Management LP raised its holdings in IDEXX Laboratories by 46.7% in the third quarter. Quantinno Capital Management LP now owns 14,756 shares of the company's stock valued at $7,455,000 after acquiring an additional 4,695 shares in the last quarter. Royal London Asset Management Ltd. raised its stake in shares of IDEXX Laboratories by 2.2% in the 3rd quarter. Royal London Asset Management Ltd. now owns 103,072 shares of the company's stock valued at $52,074,000 after purchasing an additional 2,189 shares in the last quarter. Motley Fool Asset Management LLC grew its stake in IDEXX Laboratories by 5.3% in the third quarter. Motley Fool Asset Management LLC now owns 3,930 shares of the company's stock worth $1,947,000 after purchasing an additional 198 shares in the last quarter. IHT Wealth Management LLC grew its stake in IDEXX Laboratories by 32.9% in the third quarter. IHT Wealth Management LLC now owns 666 shares of the company's stock worth $335,000 after purchasing an additional 165 shares in the last quarter. Finally, Janus Henderson Group PLC increased its holdings in IDEXX Laboratories by 0.4% in the third quarter. Janus Henderson Group PLC now owns 11,834 shares of the company's stock valued at $5,978,000 after buying an additional 53 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Insider Activity

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the transaction, the director now directly owns 905 shares of the company's stock, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.18% of the company's stock.

Wall Street Analysts Forecast Growth

IDXX has been the topic of a number of research analyst reports. Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. Piper Sandler reaffirmed a "neutral" rating and issued a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. StockNews.com upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, November 28th. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They issued an "outperform" rating and a $500.00 price target on the stock. Finally, Stifel Nicolaus decreased their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a report on Thursday, October 10th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has an average rating of "Moderate Buy" and a consensus price target of $539.63.

IDEXX Laboratories Stock Performance

NASDAQ IDXX traded down $5.96 on Tuesday, hitting $444.72. The stock had a trading volume of 680,674 shares, compared to its average volume of 512,501. The company's 50-day moving average is $443.38 and its two-hundred day moving average is $473.39. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $583.39. The stock has a market cap of $36.42 billion, a price-to-earnings ratio of 42.89, a P/E/G ratio of 3.98 and a beta of 1.37. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. During the same period in the previous year, the firm posted $2.53 earnings per share. The business's revenue was up 6.6% on a year-over-year basis. On average, analysts expect that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.